Genetic Mutations and Family History
The Basser Center for BRCA hosted a panel discussion of the latest breakthroughs and discoveries for BRCA-related cancers.
Learn more about the research interests of Nicolette Rodriguez, M.D., M.P.H., one of the young investigators Let’s Win sponsored at AACR.
Dr. Andrew Aguirre and other researchers from Dana-Farber and the Broad Institute are looking at the RAS pathway for a new target.
A new trial targets patients with advanced solid tumors, including pancreatic cancer, with an MTAP-deletion genetic mutation.
Dr. Nicolette Rodriguez leads the REGENERATE study to find the best ways to get more Black and Latinx Americans genetic testing for cancer.
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
A clinical trial looks at whether molecular subtyping of tumors is effective in determining the best pancreatic cancer treatment.
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.